Non-Alcoholic Steatohepatitis (NASH) Market Forecast 2026–2035: Data Trends and Industry Insights
Uncover key drivers, emerging technologies, and competitive movements shaping the non-alcoholic steatohepatitis (nash) market from 2026–2035 with trusted insights from The Business Research Company
By how much is the Non-Alcoholic Steatohepatitis (NASH) Market expected to grow between 2026 and 2030?
The market for non-alcoholic steatohepatitis (nash) has experienced rapid expansion in recent years. This market is projected to expand from $6.06 billion in 2025 to $8.04 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 32.7%. Factors contributing to its historical growth include insufficient public understanding of nash, the absence of potent treatment remedies, a strong dependence on lifestyle changes, the widespread occurrence of metabolic conditions, and a fragmented market structure.
The non-alcoholic steatohepatitis (nash) market is projected to experience rapid expansion over the coming years. This market is anticipated to reach a valuation of $24.32 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 31.9%. Factors contributing to this growth during the forecast period include progress in targeted treatments, a rise in healthcare spending, the increasing use of non-invasive diagnostic methods, an expanding range of pharmaceutical products, and more partnerships for research and development. Key trends defining the forecast period involve the increasing occurrence of obesity and type 2 diabetes, the creation of innovative non-invasive diagnostic instruments, intensified research into liver fibrosis treatments, an uptick in personalized and targeted medication approaches, and the broadening of hospital and retail pharmacy networks.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp
Which Drivers Are Influencing Market Acceleration In The Non-Alcoholic Steatohepatitis (NASH) Market?
The escalating occurrence of obesity is propelling the demand for the non-alcoholic steatohepatitis (NASH) market in the future. Obesity constitutes an unhealthy or excessive accumulation of body fat, or a body weight surpassing what is considered healthy or typical for an individual’s height, posing considerable health risks. With non-alcoholic fatty liver disease becoming more widespread due to the escalating obesity pandemic, NASH is likely to emerge as the leading cause of severe liver disease over the next few decades, thereby increasing the requirement for NASH treatments and related pharmaceuticals. For instance, in May 2025, data from the Government Digital Service, a UK-based government body, revealed that from 2023 to 2024, the prevalence of overweight (including obesity) among adults was higher in men (69.7%) than women (59.2%), whereas the prevalence of obesity in adults was greater in women (26.9%) compared to men (26.2%). Hence, the increase in obesity cases will fuel the growth of the non-alcoholic steatohepatitis (NASH) market.
What Leading Segments Are Studied In The Non-Alcoholic Steatohepatitis (NASH) Market?
The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –
1) By Dosage Form: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
Which Competitive Trends Are Impacting The Structure Of The Non-Alcoholic Steatohepatitis (NASH) Market?
Major companies in the non-alcoholic steatohepatitis (NASH) market are developing thyroid hormone receptor-beta (THR-beta) agonists with the aim of boosting liver metabolism, diminishing liver fat buildup, and enhancing liver function. Thyroid hormone receptor-beta (THR-beta) agonists are compounds that specifically activate the thyroid hormone receptor-beta subtype, a critical receptor involved in the regulation of metabolism, growth, and development. For instance, in March 2024, the Food and Drug Administration, a US-based regulatory body, approved Rezdiffra (resmetirom), which is a thyroid hormone receptor-beta agonist, as the first treatment for adults with noncirrhotic NASH experiencing moderate to advanced liver scarring (fibrosis). By selectively activating the THR-beta receptor, Rezdiffra helps manage lipid metabolism, leading to a reduction in intrahepatic triglycerides and overall liver fat accumulation.
Which Leading Companies Dominate The Non-Alcoholic Steatohepatitis (NASH) Market Share?
Major companies operating in the non-alcoholic steatohepatitis (nash) market are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens
Access The Complete Report For Deeper Market Insights:
How Does The Non-Alcoholic Steatohepatitis (NASH) Market Perform Across Major Global Regions?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2025. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Non-Alcoholic Steatohepatitis (NASH) Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis (NASH) Market 2026, By The Business Research Company
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Biomarkers Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
